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Enhancing immunogenicityThe vaccinia virus (VACV) entry–fusion complex (EFC) is composed of at least nine membrane proteins.
Immunization of mice with individual EFC genes induced corresponding protein-binding antibody but failed
to protect against VACV intranasal challenge and only DNA encoding A28 elicited low neutralizing antibody.
Because the A28 and H2 proteins interact, we determined the effect of immunizing with both genes
simultaneously. This procedure greatly enhanced the amount of antibody that bound intact virions,
neutralized infectivity, and provided partial protection against respiratory challenge. Neither injection of A28
and H2 plasmids at different sites or mixing A28 and H2 sera enhanced neutralizing antibody. The
neutralizing antibody could be completely removed by binding to the A28 protein alone and the epitope was
located in the C-terminal segment. These data suggest that the interaction of H2 with A28 stabilizes the
immunogenic form of A28, mimicking an exposed region of the entry–fusion complex on infectious virions.National Institutes of Health,
.
lation, National Institute of
567-0085, Japan.
Inc.Published by Elsevier Inc.Introduction
Poxviruses are large, complex, enveloped DNA viruses that replicate
in the cytoplasm of infected cells (Moss, 2007). The best-characterized
members belong to the orthopoxvirus genus of the chordopoxvirus
subfamily, which includes variola virus and vaccinia virus (VACV)—the
causative agent of smallpox and the vaccine virus used to prevent
smallpox, respectively (Damon, 2007). Two major infectious forms of
VACV have been characterized. The mature virion (MV) contains more
than 80 proteins (Chung et al., 2006; Resch et al., 2007; Yoder et al.,
2006) and consists of a nucleoprotein core surrounded by a lipoprotein
membrane (Condit et al., 2006). The MV can be released by cell lysis or
wrapped by modiﬁed trans-Golgi or endosomal cisternae, which
facilitate virion movement to the cell periphery and exocytosis as the
enveloped virion (EV) (Smith and Law, 2004). Thus, the EV is essentially
aMVwith an additional lipoproteinmembrane. The EVmembrane does
not fuse with the cell membrane but must be disrupted to expose the
MV (Law et al., 2006).
More than 20 viral proteins are associated with the MV membrane
(Moss, 2007). There is evidence that four MV membrane proteins
(A26, A27, D8, H3) are involved in attachment to the cell by binding to
glycosaminoglycans (Chung et al., 1998;Hsiao et al., 1999; Lin et al., 2000)
or laminin (Chiu et al., 2007), while others are dedicated to membranefusion (Moss, 2006). Nine of the fusion proteins, namely A16 (Ojeda et al.,
2006b), A21 (Townsley et al., 2005b), A28 (Senkevich et al., 2004), G3
(Izmailyan et al., 2006), G9 (Ojeda et al., 2006a), H2 (Senkevich and
Moss, 2005), J5 (Senkevich et al., 2005), L5 (Townsley et al., 2005a), and
the recently discovered O3 (Satheshkumar andMoss, 2009) form a stable
entry–fusion complex known as the EFC. Of the three additional entry
proteins, L1 (Bisht et al., 2008) and F9 (Brown et al., 2006) have a weak
association with the complex; the association of the I2 entry protein
(Nichols et al., 2008) has not been analyzed. The overall organization of
the EFC is unknown, but there is evidence for direct interactions between
the A28 and H2 (Nelson et al., 2008b) and between the A16 and G9
(Wagenaar et al., 2008) components.
Of the six viral proteins associated with the EV membrane, four
(A33, A34, B5, and F13) are involved in MV wrapping, intracellular
movement, and the formation of “actin tails” on the cell surface
(Smith et al., 2002). Two additional proteins, A56 and K2, are present in
both the EVmembrane and the plasmamembrane; they interactwith the
A16 and G9 components of the EFC (Wagenaar and Moss, 2007;
Wagenaar et al., 2008) and function to prevent fusion of progeny virions
with infected cells (Turner andMoyer, 2008;Wagenaar andMoss, 2009)
and fusion of infected cells with each other (Ichihashi and Dales, 1971;
Law and Smith, 1992; Turner and Moyer, 1992; Zhou et al., 1992).
The use of cowpox or VACV to prevent smallpoxwas a pivotal event in
the history of vaccinology (Fenner et al., 1988). Nevertheless, because of
the implementation and early success of the vaccine before modern
immunology, we know relatively little regarding the mechanism of
protection against smallpox (Kennedy et al., 2009). Speciﬁc antibody and
memory B and T cells persist for decades in humans after smallpox
vaccination (Crotty et al., 2003;Hammarlundet al., 2003; Putz et al., 2005;
Fig. 1. Western blots showing expression and immunogenicity of EFC proteins. (A)
Expression of VACV EFC genes from plasmids. BS-C-1 cells were transfected with the
empty vector plasmidor a plasmid expressing A28,H2, A16, L5, G3, or A21, harvested after
24 h and analyzed by SDS–PAGE under reducing conditions. Following membrane
transfer, strips were incubated with the corresponding polyclonal antibody and bound
proteins were detected by chemiluminescence. Numbers: 1, empty plasmid vector; 2,
plasmid encoding indicated EFC gene. Positions and masses in kDa of protein markers are
at the left of each panel. (B) Reactivity of serum from a rabbit immunized with VACV.
Western blotting was performed as in panel A except that the membrane was incubated
with antiserum from a rabbit that had been immunized with live VACV (Wyatt et al.,
2008). The blot was developed with chemiluminescence. The proteins encoded by the
plasmids are indicated above each lane. EV refers to empty vector. (C) Antibody responses
of mice following DNA immunizations. Pooled mouse sera (n=10) obtained 2 weeks
following the 3rd immunization of A28, H2, A21, G3, G9, or J5 genes were used to probe
Western blots containing the corresponding protein from transfected BS-C-1 cell lysates
using infrared ﬂuorescence detection (LI-COR Biosciences, Lincoln, NE).
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suggest that interferons, natural killer cells, CD4 and CD8 T cells, and
antibodyareall involved in clearingaprimaryorthopoxvirus infection, but
that antibodies are central for prevention of a secondary infection or a
primary infection following vaccination (Panchanathan et al., 2008). MVs
can be neutralizedwith antibodies to A27 (Rodriguez and Esteban, 1987),
D8 (Hsiao et al., 1999), H3 (Lin et al., 2000), L1 (Wolffe et al., 1995), and
A28 (Nelson et al., 2008a). EVs can be neutralized directly or in a comet
assaywith antibody toB5 (Galmiche et al., 1999) andA33 (Galmicheet al.,
1999). Immunizationwith individual proteins or DNA encoding them can
partially protect mice against VACV infection (Davies et al., 2005b; Fogg
et al., 2004; Galmiche et al., 1999; Hooper et al., 2000; Lai et al., 1991).
Combinations of at least oneMVand one EV protein, however, achieve far
greater protection than individual proteins (Fogg et al., 2004; Hooper
et al., 2000; Hooper et al., 2003). A similar beneﬁt was obtained by
prophylactic administration of polyclonal and monoclonal antibodies to
both MV and EV proteins (Lustig et al., 2005).
We are interested in determiningwhether the components of the EFC
can induce neutralizing antibodies. A previous report showed that rabbits
immunized multiple times with a secreted recombinant form of the A28
protein with Freund's adjuvant produced low levels of neutralizing
antibody (Nelson et al., 2008a). In the present study, we used a DNA
vaccine approach to compare the immunogenicity of eight EFC proteins
alone and in combinations. Only DNA encoding A28 induced a barely
measurable level of neutralizing antibody, whichwasmarkedly increased
when administered with DNA encoding H2. No other individual or
combination of EFC gene immunizations lacking H2 enhanced the
neutralizing antibody response. In addition, only the combination of
A28 and H2 provided partial protection to a VACV intranasal challenge.
The neutralizing antibody frommice immunized with A28 and H2 genes
was depleted by adsorptionwith immobilized A28 protein alone, and the
epitope was located in the C-terminal segment of A28. H2 and A28 have
been shown to physically interact (Nelson et al., 2008b), suggesting that
this interaction enhances immunogenicity by stabilizing the neutralizing
epitope on the latter.
Results
Construction of plasmids expressing proteins of the poxvirus EFC
The recently described EFC on the VACVMV is comprised of at least
nine viralmembrane proteins (A16, A21, A28, G3, G9, H2, J5, L5, andO3)
that are conserved in all poxviruses. We constructed plasmids
expressing each of these genes, except for O3, which had not been
discovered when these experiments were initiated, for subsequent
mouse immunization. Since these proteins are not glycosylated during a
VACV infection, potential glycosylation sites were mutated and the
sequences were codon optimized before cloning into a eukaryotic
expression vector, VRC8400, with a cytomegalovirus promoter adapted
for expression inmice (Barouch et al., 2005). After transfectionof BS-C-1
cells with the individual plasmids, expression of A28, H2, A16, L5, G3,
and A21 was documented by Western blotting using speciﬁc anti-
peptide rabbit polyclonal antibodies (Fig. 1A). Protein expression was
greater after plasmid transfections than after VACV infection (data not
shown). Expression of J5 and G9 could not be assessed in this
experiment because of the absence of speciﬁc rabbit antibody but was
conﬁrmedbyothermeansbelow.Antiseraproducedby infecting rabbits
with VACV reacted with A28, H2, and J5 in addition to L1 (Fig. 1B);
however, the other EFC proteinswere not detected suggesting that they
are not highly immunogenic during a virus infection or that the
antibodies do not react with the denatured proteins on Western blots.
Immunization of mice with individual plasmids expressing EFC proteins
Gold beads were coated with plasmids and then injected with a gene
gun into 7-week-old BALB/c mice. After three immunizations at intervalsof 3 weeks, the mice were bled and the pooled sera tested by probing
Western blots prepared by SDS–polyacrylamide gel electrophoresis
(PAGE) of lysates of transfected cells. Western blotting revealed
antibodies to A21, A28, G3, G9, H2, and J5 (Fig. 1C); the A16 band was
faint and L5 was not detected (not shown). This experiment conﬁrmed
the expressionofG9 and J5 by the plasmid expression vectors. In addition,
a low level of antibody to each of the proteins except A21was detected by
enzyme-linked immunosorbent assay (ELISA) using puriﬁed VACV as the
antigen (data not shown).
Neutralizing activity was determined by a ﬂow cytometry assay that
measures the ability of serum to prevent infection of cells by a
recombinant VACV encoding enhanced green ﬂuorescent protein
(GFP) (Earl et al., 2003). Sera frommice immunized with A28 exhibited
low neutralization with the half-maximal inhibitory serum concentra-
tion (IC50) of 82, whereas the IC50 of the other sera were b50, the cutoff
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immunized in parallel with gold beads coated with a plasmid that
expressed L1 had an IC50 of 868.
At 3 weeks after the last gene gun immunization, the mice were
challengedwith 104 plaque-forming units (PFUs) of VACV strainWestern
Reserve by the intranasal route andweighed daily to assess disease. None
of the plasmids expressing individual EFC proteins provided signiﬁcant
protection (Figs. 2AandB). Partial protectionwasprovidedby theplasmid
expressing L1 as previously described (Shinoda et al., 2009).Combination of A28 and H2 provided partial protection against weight
loss after VACV challenge
Since the results obtainedwith the individual genes indicated low or
no neutralizing activity, we tried gene combinations. Plasmids
expressing A28 and H2 were chosen ﬁrst because these two proteins
are known to interact directly (Nelson et al., 2008b). Either the plasmids
expressing A28 and H2were mixed before coating the beads (A28/H2)
or the beads were coated separately and then mixed (A28+H2). In the
experiment depicted in Fig. 2C, separate groups of animals were
immunized four times at intervals of two weeks with beads containing
A28/H2, A28+H2, A28 alone, H2 alone, L1 as a positive control, or
empty plasmid vector. As above, the mice were challenged intranasally
with 104 PFU of VACV and weighed daily. Mice immunized with either
A28/H2 or A28+H2 exhibited signiﬁcantly less weight loss at days
8 and9 (p≤0.032) thanmice immunizedwithA28orH2aloneor empty
vector (Fig. 2C). The protection achieved with the A28 and H2 plasmidFig. 2. Partial protection of immunized mice. (A, B) Groups of 10 mice were immunized 3 t
indicated plasmid. At 3 weeks after the last immunization, mice were challenged intranasally
representative experiment are plotted, and error bars are shown. The weight control mice w
panels except that the gold beads contained individual or combinations of plasmids (1 µg e
were mixed before binding to gold beads; a plus signiﬁes that plasmids were individually b
were vaccinated four times at 2-week intervals and challenged with 2×104 PFU of VACV acombinationswere similar to that resulting from immunizationwith the
L1 plasmid.
Encouraged by results with A28 and H2, we tried additional
combinations. The eight EFC proteins can be divided into two subsets:
A21, A28, G3, H2, and L5 have N-terminal transmembrane domains and
A16,G9, and J5are sequence-relatedandhaveC-terminal transmembrane
domains (Senkevich et al., 2005). In addition, A16 and G9 were found to
interact with each other (Wagenaar et al., 2008). Based on these criteria,
we made six plasmid immunization groups: (i) A28/H2, (ii) A21/L5/G3,
(iii) A16/G9/J5, (iv) all eight EFC genes, (v) L1, and (vi) empty vector.
Micewere immunized four timesat3-week intervals andwerechallenged
3 weeks later. Themice receiving A28/H2, the eight EFC genes, or L1were
better protected than those receiving A21/G3/L5, A16/G9/J5, or the
empty vector (Fig. 2D). At day 8, the A28/H2 group and eight EFC gene
group lost signiﬁcantly less weight than the mice immunized with the
empty vector (p≤0.02 and p≤0.032, respectively) or A16/G9/J5
(p≤0.008 for both). Thus, partial protection correlated with the
administration of the genes encoding both A28 and H2.
Analysis of antibodies induced by A28 and H2 immunizations
Sera from immunized mice were examined for the presence of
binding and neutralizing antibodies.When tested for binding to the A28
protein by enzyme-linked immunosorbent assay (ELISA), sera from the
single A28 and combination (A28/H2 and A28+H2) groups had
equivalent titers (Fig. 3A). Similarly, when tested against H2 protein,
each of the H2 immunization groups had equivalent titers (Fig. 3A). A
striking differencewas noted, however, when the serawere tested in animes at 3-week intervals by gene gun delivery with gold beads containing 1 µg of the
with 104 PFUs of VACV and weighed daily. The percentages of the initial weights from a
ere not immunized or challenged. (C, D) The protocol was similar to that of the above
ach except for 0.5 µg in 8 gene combination in panel D). Slashes indicate that plasmids
ound to gold beads and the beads were mixed before injection. The mice (n=5 to 10)
nd weighed daily.
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10-fold higherwhen themicewere immunizedwith plasmids encoding
A28/H2 or A28+H2 compared to either plasmid alone (Fig. 3A).
Moreover, the groups immunized with A28/H2 or A28+H2 induced
much higher neutralizing antibody than mice immunized with either
plasmid alone (Fig. 3B), indicating a direct correlation between the
ability of the antibody to bind VACV and neutralize infectivity. In
contrast,mixing sera frommice immunized separatelywithA28 andH2
did not increase the neutralizing activity (Fig. 3B) and mice immunized
with A28 and H2 at separate sites raised little neutralizing antibody
(Fig. 3C). Furthermore, sera from mice immunized with plasmids
expressing A21/L5/G3 and A16/G9/J5 had no measurable neutralizing
activity (not shown).
To evaluate whether the combination of A28 and H2 plasmids was
uniquely able to induce neutralizing antibody, mice were immunized
with A28/H2, all eight plasmids or with seven plasmid mixtures that
lacked A28 or H2. The amount of each individual plasmid was 0.5 µg,
regardless of the total number of plasmids administered. Only the sera
frommice that received bothA28 andH2hadmuchneutralizing activity
(Fig. 3D).Noneof theother EFCproteinswasable to substitute forA28or
H2. The neutralization titer obtained with all eight plasmids was less
than with A28/H2 alone. Furthermore, immunization with seven
plasmids lacking either A28 or H2 did not induce neutralizing antibody.
The titer with A28/H2 was lower than in the previous experiments,
probably because half the amount of DNA was used for immunizations.Determination of the target of VACV binding and neutralizing antibodies
We considered two general explanations for the synergistic effects of
A28andH2on the inductionof virionbinding andneutralizing antibodies.
One possibility was that the targeted epitope comprises part of the A28-
H2 interaction site and is not present in either protein alone. Another is
that one of the two proteins stabilizes an immunogenic conformation of
the other. Protein adsorption experiments were carried out in an attempt
to differentiate between these two models. Pooled serum from mice
immunized with A28/H2-coated gold beads was adsorbed with puriﬁed
A28 or H2 protein-coated magnetic beads, and the supernatant fractions
were analyzed using immobilized A28 andH2 proteins. The A28- andH2-
coated beads removed the corresponding antibodies without depleting
the noncorresponding ones (Figs. 4A and B). However, the A28-depleted
sera failed to bind to immobilized VACV, whereas the H2-depleted sera
lost no reactivity (Fig. 4C). In addition, the A28-depleted sera lost all VACV
neutralizing activity, which was retained by the H2-depleted sera
(Fig. 5A). The adsorption of neutralizing activity was proportionate to
the concentration of A28 (Fig. 5B). Nonspeciﬁc adsorption of VACV
binding and neutralizing activity by the A28-coated beads was ruled out
by using L1 antiserum generated in a similar manner (data not shown).Fig. 3. Induction of binding and neutralizing antibodies. (A) ELISA assays. Sera obtained
after the fourth DNA immunization (corresponding to Fig. 2C) were pooled and assayed
by ELISA. The DNA used for immunization is indicated on the left and the immobilized
protein (A28 or H2) or intact virions (VACV) on the top. A28/H2 refers to plasmids
attached to the same beads and A28+H2 refers to mixtures of beads containing A28
and beads containing H2. (B) Neutralization titers after same-site injections. The sera
used in panel A were tested by ﬂow cytometry for ability to neutralize recombinant
VACV expressing GFP. Sera mix refers to mixing equal volumes of sera from mice
immunized with A28 DNA alone and with H2 alone. The data for all samples except the
sera mix are the averages from four independent assays, each done in duplicate. Error
bars are shown. The sera mix was done once in duplicate. (C) Comparison of
neutralization titers after same and different site immunizations. Immunizations were
as described in Fig. 2C except that some received A28 and H2 in the same site (ss) and
others in different abdominal sites (ds). The assay was performed twice each time in
duplicate and averages with error bars are shown. (D) Neutralization titers after
multigene immunizations. Mice were immunized with 0.5 µg of each A28/H2, mixture
of all eight plasmids, or seven gene combinations that excluded A28 or H2. Averages of
three assays, one which was done in duplicate are shown with error bars.The VACV neutralization epitope resides in the C-terminal region of the
A28 protein
To determine the location of the VACV neutralizing epitope on the
A28 protein, plasmids encoding N-terminal and C-terminal truncations
were made. In each construct, a signal peptide replaced the 26-amino
acid transmembrane domain and a six-histidine tag was present at the
Fig. 4. Adsorption of protein and virion-binding antibodies. Samples of pooled sera,
following the fourth A28/H2 DNA immunization, were incubated with A28 or H2
protein-coated magnetic beads, and the depleted sera were analyzed in duplicate by
ELISA to immobilized A28 protein (A), H2 protein (B), or intact VACV virions (C).
Fig. 5. Adsorption of VACV neutralizing antibody. (A) Samples of pooled serum following
the fourth A28/H2 DNA immunization were incubated with A28 or H2 coated magnetic
beads and the depleted sera tested for ability to neutralize VACV. Averages of duplicate
determinations are shown. EV, refers to empty vector. (B) Magnetic beads were coated
with ﬁve-fold serial dilutions of A28 protein, incubatedwith pooled A28/H2 sera, and the
depleted sera tested for VACV neutralization as in panel A. The percentage of neutralizing
activity remaining after adsorption is plotted. Averages of duplicate determinations
are shown.
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plasmids. Because the truncated proteins were not efﬁciently secreted,
the cell lysates were analyzed by SDS–PAGE andWestern blotting with
antibody to the histidine tag (Fig. 6B). The mutant proteins were
expressed to similar levels except for the low yields of A28T-4 and
A28T-5. The proteins were bound to magnetic afﬁnity beads, which
were then incubated with sera from mice that had been immunized
with the A28/H2 plasmid. The N-terminal truncated proteins A28T-1,
A28T-2, and A28T-3 depleted the serum of neutralizing antibody. In
contrast, none of the proteins with C-terminal truncations (A28T-5,
A28T-6,A28-T7, orA28T-8)depleted the serumofneutralizing antibody
(Fig. 6C). The inability of A28T-5 and possibly A28T-4 to remove
neutralizing antibody might have been due to their lower expression
and recovery after afﬁnity puriﬁcation than the other proteins.
Discussion
Identiﬁcation of the targets of neutralizing antibody is important for
understanding themechanismof immunity to poxviruses and developing
safer poxvirus vaccines. In view of the complexity of VACV and the large
number of proteins associatedwith theMVmembrane, it is not surprisingthat multiple targets of neutralizing antibody have been found. The latter
include proteins involved in virus attachment to cells, e.g., A27 (Rodriguez
and Esteban, 1987), H3 (Lin et al., 2000), and D8 (Hsiao et al., 1999) and
two proteins involved in entry and membrane fusion, namely L1
(Wolffe et al., 1995) and A28 (Nelson et al., 2008a). Attempts have been
made to determine the dominant neutralizing antibody in sera from
smallpox vaccine recipients. However, modest or no reduction in overall
neutralizing titers was obtained by depletion of antibodies to H3, L1, and
A27 (Benhnia et al., 2008; He et al., 2007; Putz et al., 2006). These results
can be interpreted in several ways: (i) there are low amounts of
neutralizing antibody tomanydifferent targets, (ii) themajor neutralizing
target protein has not yet been identiﬁed, or (iii) the dominant
neutralizing antibody recognizes a complex on the virion surface.
We were interested in determining whether the proteins involved in
virus entry and membrane fusion are immunogenic and targets of
neutralizing antibody. Antibodies from humans, macaques, andmice that
were immunized with VACV and screened against a complete array of
VACVproteinsmade in Escherichia colidetected L1 andoccasionally traces
of EFC proteins A21, A28, H2, and L5 (Davies et al., 2005a; Davies et al.,
2008). For the present study, we cloned genes encoding eight of the nine
known EFC proteins and L1 into eukaryotic expression plasmids. Using
transfected cell lysates for Western blotting, we detected antibodies to
A28,H2, J5, and L1 in sera of rabbits that hadbeen infectedwithVACV. The
Fig. 6. Localization of VACV neutralizing epitope on the A28 protein. (A) Diagram of A28
truncations. Representation of A28 protein with amino acid numbers is shown at the top.
A28T-1 shows the A28 protein with replacement of the 26-amino acid N-terminal
transmembrane domain by the Ig κ-chain signal peptide sequence (SS) and addition of a
six-histidine (6xHis) tag at the C-terminus. A28T-1 to A28T-4 constructs contain serial
N-terminal truncations but retain the signal peptide and six-histidine tag. A28T-5 to
A28-T7 constructs have serial C-terminal truncations and A28T-8 has both N- and
C-terminal truncations. (B) Western blot. Plasmids encoding truncated proteins were
transfected into HeLa cells and the lysates were analyzed by Western blotting with
antibody to the histidine tag. (C) The A28 proteins diagrammed in panel Awere expressed
by transfection and bound to beads via the six-histidine tag. The beads were incubated
with A28/H2 sera and the depleted sera were tested for neutralizing activity. A
representative of three assays is shown.
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some of the EFC proteins.
Gene gun immunizations were used to determine whether
individual components of the EFC or combinations of EFC proteins
induce neutralizing antibodies in mice. The EFC genes were codon
optimized, Asn-X-Ser/Thr sequences altered to prevent unnatural
glycosylation and the transmembrane domains retained. Although
most individual plasmids induced antibody that bound to the
homologous protein, only DNA encoding A28 induced a low level of
neutralizing antibody. However, neutralizing antibody was greatly
increased when plasmids encoding A28 and H2 were administered
together. No other combination of EFC genes, including a mixture of
sevengenes lackingeitherA28orH2, inducedneutralizingantibody. It is
possible that the majority of EFC proteins may not be targets of
neutralizing antibody because of their arrangement in the MV
membrane. Alternatively, many of the proteins expressed by DNA
immunization may be improperly folded. Therefore, our most signiﬁ-
cant ﬁndings relate to the induction of neutralizing antibody to A28 andparticularly its enhancement by H2 rather than the negative ﬁndings
regarding the other EFC proteins.
The sera from mice that were immunized with DNA expressing A28
alone or H2 alone contained equivalent amounts of protein-binding
antibody as sera from mice that were immunized with DNA expressing
both proteins. However, the sera from the combined immunization
containedmuchhigher amounts of antibodies that bound to intact virions
as determined by an ELISA and neutralized VACV infectivity. The
synergistic effect of H2 and A28 on the induction of neutralizing rather
than protein binding antibody could have several explanations. The
possibility that antibodies to each of the proteins acted synergisticallywas
ruled out by serum mixing experiments. A requirement for a direct
association of A28 and H2 proteins was consistent with the enhanced
induction of neutralizing antibodywhen the two DNAswere on the same
beads or on separate beads thatwere injected at the same site and the lack
of enhancementwhen theyweredelivered todifferent sites on themouse.
These results can be best explained by the association of A28 and H2,
which has been demonstrated to occur when these two proteins are
expressed by DNA transfection of uninfected cells (Nelson et al., 2008b).
With this explanation in mind, we considered the possibility that the
neutralizing epitope is at the A28-H2 interface and hence not present in
either A28 or H2 alone or that the epitope is located onH2 or A28 but that
the immunogenic conformation is stabilized by the protein–protein
interaction. To investigate these possibilities, A28 and H2 were bound
separately to beads, which were used to adsorb antibodies from sera of
mice that were immunized with both A28 and H2 DNA. The A28 and H2
beads efﬁciently depleted the antibody that bound to A28 and the H2,
respectively. However, only the A28 beads depleted the neutralizing
antibody, consistent with the second hypothesis.
Our data indicate that the C-terminal region of A28 either contains
the neutralizing epitope elicited by immunizationwith A28 andH2 or is
important for the correct folding of a conformational epitope. In a
previous study, a synthetic A28 peptide representing amino acids 73–92
was able to bind neutralizing antibody obtained by repeatedly
immunizing a rabbit with a soluble form of A28 in adjuvant. We were
unable to capture the neutralizing antibody prepared by DNA
immunizations with a panel of peptides attached to plastic, including
the one above (K.S., unpublished data). However, truncated A28
proteins missing the N-terminal 26, 46 or 66 amino acids but not 86
amino acids still depleted the A28/H2 neutralizing antibody, consistent
with an epitope including amino acids amino acids 73–92. Further
studies are needed to determine whether the targets of neutralizing
antibody elicited by soluble A28 protein and by membrane-associated
A28/H2 are identical.
The present study was directed to the discovery of targets of
neutralizing antibody and no efforts were made to determine whether
the modest protection of BALB/c mice to a nonlethal VACV challenge
correlated with T-cell immunity in addition to neutralizing antibody.
Passive transfer experiments were not attempted because of the low
neutralizing antibody titers, limitations in quantity of mouse sera, and
weak protection achieved. In a very recent study, cowpox genetic
sequences derived from the whole genome were screened for their
ability to protect against a cowpoxvirus infection of C57Bl/6mice byDNA
immunization (Borovkov et al., 2009). Nine immunogens scored
positively, and these included nonmembrane as well as membrane
components. Each of the nine was shown to induce T-cell responses and
protein binding antibody, but virus neutralizing activitywas not analyzed.
Curiously, no homologs of the VACV protective immunogens, which had
been tested in BALB/cmice,were among the nine newcowpoxprotective
immunogens, which included two EFC proteins, namely G9 and J5. Since
cowpox virus and VACV are closely related, it is possible that the different
results relate to the Th1 and Th2 biases of C57Bl/6 and BALB/c mice,
respectively (Locksley et al., 1987; Mosmann and Coffman, 1989).
In conclusion, our data conﬁrm a previous report (Nelson et al.,
2008b) that A28 is a target of neutralizing antibody and demonstrate by
DNA immunizations that coexpression of H2 greatly increases the
47K. Shinoda et al. / Virology 405 (2010) 41–49amount of A28 virion binding and neutralizing antibody. A likely
explanation is that the known interaction of H2 with A28 stabilizes an
immunogenic conformation of A28. Presumably in solution or attached
to beads through an epitope tag, A28 is ﬂexible enough to adopt many
different conformations including ones that interact with the antibody,
providing an explanation for the difference between immunogenicity
and antigenicity.
Materials and methods
Cell cultures and viruses
BS-C-1 cells (ATCC CCL-26) and monolayer and suspension cultures
of HeLa S3 (ATCC CCL-2.2) were grown using standard procedures.
VACV strainWestern Reserve (ATTC VR1354) and VACV expressingGFP
(Earl et al., 2003) were propagated as described (Earl et al., 1998; Earl
and Moss, 1998).
Construction of plasmids
The A28, H2, A21, L5, G3, A16, G9, and J5 open reading frame
sequences of VACV strainWestern Reserveweremodiﬁed bymammalian
codon optimization, removal of potential glycosylation sites, and inserted
into pVRC8400 (Barouch et al., 2005) by GENEART (Regenburg,
Germany). The plasmid expressing L1, used as a control, was previously
described (Shinoda et al., 2009). Plasmids expressing truncations of the
A28 gene sequencewere constructed as follows: A28T-1, A28T-2, A28T-3,
and A28T-4 were truncated 26, 46, 66, or 86 amino acids, respectively,
from the N-terminus of A28; A28T-5, A28T-6, and A28T-7were truncated
20, 40, or 60 amino acids, respectively, from C-terminus of A28; A28T-8
was truncated66and40aminoacids fromtheN- andC-termini ofA28.All
genes encoded a murine Ig κ-chain signal sequence (Coloma et al., 1992)
at theN-terminal end and a six-histidine tag at the C-terminus assembled
by PCR ampliﬁcation with terminal PstI and NotI sites, and inserted into
the corresponding sites of pVRC8400.
Protein and antibodies
Secreted A28 or H2 protein, in which the honeybee melittin signal
peptidewas substituted for the transmembranedomainat theN-terminus
and a six-histidine tag was at the C terminus, was expressed by
recombinant baculovirus in insect cells and puriﬁed on Ni-NTA agarose
(Qiagen, Valencia, CA) as previously described (Nelson et al., 2008a).
Anti-A28 and H2 polyclonal antibodies were obtained by immunizing
rabbitswith solubleA28orH2protein (Nelsonet al., 2008a). Antibodies to
A21 (Townsley et al., 2005b), L5 (Townsley et al., 2005a), A16 (Ojeda et al.,
2006b), and G3 were produced in rabbits with peptides from the
corresponding proteins. Tetra-His mouse antibody (Qiagen) was used for
Western blotting of proteins expressed with six-histidine tags.
Western blotting
BS-C-1 orHeLa cellswere transfectedwith 1.5 μg of plasmid in 10 µl of
Lipofectamine™2000 (Invitrogen, Carlsbad, CA)perwell of a 6-well plate.
After 24 h, the cells were suspended with NuPAGE® Lithium Dodecyl
Sulfate Sample Buffer (Invitrogen), sonicated, and incubated with
NuPAGE® Sample Reducing Agent (Invitrogen). The proteins were
resolved by SDS–PAGE and transferred to a polyvinylidene diﬂuoride or
nitrocellulose membrane using iBlot (Invitrogen). The membrane was
incubated with antibody to a speciﬁc protein or pooled mouse sera
(n=10) following single gene gun immunization and then anti-rabbit or
mouse IgG conjugated to horseradish peroxidase for chemiluminescence
detection (Pierce, Rockford, IL) or infrared-labeleddonkey IgGanti-mouse
for infrared imaging (Odyssey, LI-COR, Lincoln, NE).Gene gun immunization of mice
Individual cartridgeswerepreparedwith approximately 0.5 µgor 1 µg
of each plasmid with 0.5 mg of gold particles. Plasmid and 2 µm gold
particles (DeGussa, Parsippany, NY) were mixed and dried onto Tefzel
tubing (BIO-RAD) according to manufacturer's directions. Seven-week-
old female BALB/c mice were injected with DNA-coated gold particles to
three nonoverlapping sites on the shaved abdomen using a Helios gene
gun (BIO-RAD, Hercules, CA) as previously described (Shinoda et al.,
2009). There were a total of 14 gene gun immunization/challenge
experiments. The number of immunizations varied from three at 3-week
intervals to four at 2-week intervals. The challenges were intranasal with
104, 2×104, or 105 PFUs from 2 to 6 weeks after the last immunization.
Routinely, there were 5 animals per group, but in one experiment, there
were 10. Each combination of immunogens was tested at least twice and
most several times. The ﬁgures show single representative experiments
unless otherwise stated.
Antibody binding assay
Antibody binding to puriﬁed A28 or H2 protein and intact VACV
particles was carried out by ELISA (Nelson et al., 2008a) with some
modiﬁcations. For protein ELISA, individual wells of a 96-well plate
(Immulon HB plate, Thermolab System, Hertfordshire, UK) were coated
with 60 ng of puriﬁed A28 or H2 protein in 100 µl of Universal Plate
Coating Buffer (Immunochemistry Technologies, Bloomington, MN)
and incubated∼24 h at 4 °C. For VACV particle ELISA, individualwells of
a 96-well plate were coated with 106 PFU of VACV in 100 µl of Coating
Buffer. Plates were ﬁxed with 100 µl/well of 4% paraformaldehyde in
phosphate-buffered saline at room temperature. Following incubation
with diluted serum followed by anti-mouse IgG-peroxidase (Roche,
Branchburg, NJ), the plates were incubated with BM Blue substrate
(Roche) and read at 370 nm and 492 nm using SpectraMax M5
Microplate Reader and SoftMaxPro Software System (Molecular
Devices, Sunnyvale, CA). The end point was 0.1 absorbance unit after
subtraction of the background absorbance of serum alone.
Neutralization assay
Puriﬁed VACV expressing GFP was used for the neutralization assay
as described (Earl et al., 2003). The virus was incubated with serum for
1 h, followed by the addition of cytosine arabinoside-treated HeLa S3
cells to the plates. The plates were incubated for 16–18 h at 37 °C, ﬁxed
with 2% paraformaldehyde in phosphate-buffered saline, and analyzed
on a FACSCalibur ﬂow cytometer using CellQuest and FlowJo Software.
IC50 values were calculated using PRISM software (GraphPad Software,
Inc, La Jolla, CA).
Adsorption of speciﬁc antibodies from serum
For adsorption of A28/H2 sera, 10 µl (0.4 mg) of TALON Dynabeads
(Invitrogen) were incubated for 4 h at 4 °C with 6 mg of puriﬁed
histidine-tagged A28 or H2 protein. The washed beads were incubated
overnightwith35 µl of 1:10dilutedA28/H2seruminphosphate-buffered
saline at 4 °C. The beads were removed from the sera with a magnet. The
protein-adsorbed sera were used for antibody binding and neutralization
assays. For adsorption of A28/H2 sera with different amounts of A28
protein, 0.01 to 4000 ng of the latter was incubated withmagnetic beads.
The beads were incubated with A28/H2 sera as above.
Adsorption of sera with truncated A28 proteins
HeLa cells (4wells of a 6-well plate)were transfectedwith plasmids
expressing truncated proteins and Lipofectamine as described above.
After 24 h, the plates were washed and each set of 4 wells were lysed
with 600 ml of ice-cold lysis buffer (50 mM Tris, pH 8.0, 150 mM NaCl,
48 K. Shinoda et al. / Virology 405 (2010) 41–491.0% NP40, and protease inhibitor cocktail, EDTA-free (Roche). Samples
were sonicated for 30 sec three times and centrifuged at 14,000 rpm in a
Sorvall Legend RT+centrifuge (Thermo Scientiﬁc, Waltham, MA) for
30 min at 4 °C. Supernatants were used for Western blotting (10 µl of
total lysate). For adsorption studies with A28/H2 mouse sera, 240 µl of
total lysatewas incubatedwith10 mlof TALONDynabeads, incubated as
described above with mouse sera.
Statistical analysis
Weight-loss differences following VACV intranasal challenge of
immunizedmicewere assessed byMann–Whitney using PRISM software
(GraphPad Software, Inc).
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